Đánh giá kết quả điều trị và một số yếu tố liên quan trên bệnh nhân ung thư tụy giai đoạn muộn tại Bệnh viện K

Evaluate the efficacy of treatment in stage III, IV and some factors related with the pancreatic cancer at K hospital. Patients and methods: 154 patients diagnosed with locally advanced or metastatic pancreatic cancer at K hospital were divided into 3 groups: chemotherapy group may be accompanied by palliative surgical procedures; the non-chemotherapy group received palliative surgical procedures; and untreated patients’ group. Result: In the group of 38 untreated patients, the median overall survival was 3.3 months (95% confidence interval 2.9 to 3.7 months). In 22 non-chemotherapy patients who underwent Palliative surgical procedures had a median overall survival of 3.9 months (95% CI 3.1-4.8 months). In 94 patients receiving chemotherapy: We found that none of patient showed a complete response, the partial response rate was 17%, 37.2% of the patients were stable and 45.7% of the patients had progressive disease. The median progression-free survival was 3.9 months (95% confidence interval, 3.3 to 4.5 months). The median overall survival was 8.2 months (95% confidence interval, 6.5 to 9.8 months). Three hundred ninety-one cycles were administered with 154 patients, grade 3-4 toxicity per patient was 10.2% for neutropenia, 6.9% for thrombocytopenia, 7.6% for hematological toxicities, 6.9% for anemia. grade 3 for 4.2% alanine aminotransferase or aspartate aminotransferase. No patient had grade 4 for alanine aminotransferase or aspartate aminotransferase.